SecBot SecBot
8-K ·Filed Nov 4, 2026

ADCT

ADC Therapeutics SA
MIXED
Impact 6/10
Horizonmonths Processed12d 7h ago SEC0000950103-26-016945
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The FDA's benefit-risk concerns on LOTIS-5 create a binary regulatory overhang for full approval of ZYNLONTA plus rituximab in 2L+ DLBCL. Watch for the company's regulatory strategy update and FDA engagement on the LOTIS-7 Phase 3 design, which could define the next catalyst path. The strong LOTIS-7 and MZL data support compendia and breakthrough designation submissions in 2027.

DirectionMixed
Confidencemedium
Horizonmonths

ZYNLONTA

◆ Mixed Named in this 8-K
Impact
Phase
Approved (accelerated approval); Phase 3 confirmatory (LOTIS-5) completed; Phase 1b combination (LOTIS-7) ongoing
Time to market
Already on the market (FDA accelerated approval April 2021). Path to full FDA approval is uncertain after LOTIS-5 safety issues. Japan decision timeline is not specified.
Next catalyst
None dated

What to watchWatch the 68th ASH Annual Meeting (December 5-8, 2026) where multiple ZYNLONTA abstracts will be presented, including updated LOTIS-7 combination data and potentially the full LOTIS-5 dataset. Also monitor the Japan marketing authorization decision by Tanabe Pharma (filed October 29, 2026) and any FDA guidance on the path to full approval. The stock trades near $1.51 with a 52-week range of $0.78-$4.98, reflecting deep uncertainty around the regulatory path.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.64
T+0 close · Nov 4, 2026 · via day close
Latest settled
−14.02%
T+5 · $1.41 · next T+20 in 17d
Vs SPY
−17.32%
α at T+5
Latest observation
−20.26%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $1.64entry
  2. T+1 · 11d ago −3.66%α −3.97% · $1.58
  3. T+5 · 5d ago −14.02%α −17.32% · $1.41
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ADC Therapeutics announced positive clinical data from multiple ZYNLONTA trials to be presented at ASH 2026, including high response rates in LOTIS-7 (88.7% ORR) and MZL (93% ORR), alongside preliminary Q3 2026 net product revenue of $21M (up from $16M YoY) and a strengthened balance sheet following an $86.6M PIPE and debt refinancing. However, the LOTIS-5 confirmatory trial showed a Grade 5 safety imbalance (13.2% vs 4.6%) that the FDA flagged as a benefit-risk concern, creating regulatory uncertainty for full approval.

Key Financial Metrics

Revenue
$21.0M
est $19.1M · +9.9% · +31.3% YoY

Key Facts

  • Preliminary Q3 2026 ZYNLONTA net product revenue of $21M, up from $16M in Q3 2025
  • LOTIS-7 Phase 1b: 88.7% ORR and 75.3% CR in 97 evaluable r/r DLBCL patients at 10.35 months median follow-up
  • Phase 2 MZL IIT: 93% ORR and 74.4% CR in 43 evaluable patients with 90.8% two-year PFS
  • LOTIS-5 Phase 3 met primary PFS endpoint (HR 0.73, p=0.0083) but Grade 5 TEAEs were 13.2% vs 4.6% in control arm
  • FDA cited concerns regarding benefit-risk of ZYNLONTA plus rituximab from LOTIS-5; regulatory strategy update pending
  • $86.6M PIPE closed October 22, 2026; HealthCare Royalty amendment removed $150M change-of-control payment
  • Senior secured loan refinanced to $50M principal, bullet payment August 2029, no minimum liquidity covenant
  • Pro forma cash of $196M post-refinancing; expected cash runway into 2029
  • Cash and cash equivalents of $189.2M as of September 30, 2026

Financial Impact

Preliminary Q3 2026 net product revenue $21M (+31% YoY); pro forma cash $196M; $86.6M PIPE closed; debt principal reduced to $50M

revenuecashdebtdilution

Risk Factors

  • FDA benefit-risk concerns on LOTIS-5 may delay or prevent full approval and sBLA submission
  • Grade 5 safety imbalance (13.2% vs 4.6%) in LOTIS-5 could limit commercial adoption even if approved
  • Dilution from $86.6M PIPE and warrant repricing (9.8M warrants reduced to $0.10 exercise price)
  • Preliminary financials are subject to revision; actual Q3 results may differ
  • Company is pre-revenue on an operating basis; relies on ZYNLONTA for all product revenue

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000950103-26-016945
Document: dp256258_ex9902.htm0000950103-26-016945
Document: dp256258_8k.htm0000950103-26-016945
Document: 0000950103-26-016945-index-headers.html0000950103-26-016945
Document: 0000950103-26-016945-index.html0000950103-26-016945
Document: 0000950103-26-016945.txt0000950103-26-016945
8-K Data (Synthetic)0000950103-26-016945

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026